title: Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans.
abstract: Metastasis-associated protein 1 (MTA1), a negative epigenetic modifier, plays a critical role in prostate cancer (PCa) progression. We hypothesized that MTA1 overexpression in primary tumor tissues can predict PCa aggressiveness and metastasis. Immunohistochemical staining of MTA1 was done on archival PCa specimens from University of Mississippi Medical Center and University of Iowa. We found that nuclear MTA1 overexpression was positively correlated with the severity of disease progression reaching its highest levels in metastatic PCa. Nuclear MTA1 overexpression was significantly associated with Gleason > 7 tumors in African Americans but not in Caucasians. It was also a predictor of recurrent disease. We concluded that MTA1 nuclear overexpression may be a prognostic indicator and a future therapeutic target for aggressive PCa in African American men. Our findings may be useful for categorizing African American patients with a higher probability of recurrent disease and metastasis from those who are likely to remain metastasis-free.
authors.affiliation: Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Dias
authors.forename: Xinchun
authors.initials: X
authors.lastname: Zhou
authors.forename: Marina
authors.initials: M
authors.lastname: Ivanovic
authors.forename: Michael P
authors.initials: MP
authors.lastname: Gailey
authors.forename: Swati
authors.initials: S
authors.lastname: Dhar
authors.forename: Liangfen
authors.initials: L
authors.lastname: Zhang
authors.forename: Zhi
authors.initials: Z
authors.lastname: He
authors.forename: Alan D
authors.initials: AD
authors.lastname: Penman
authors.forename: Srinivasan
authors.initials: S
authors.lastname: Vijayakumar
authors.forename: Anait S
authors.initials: AS
authors.lastname: Levenson
mesh_terms: D001741:Black or African American / Q000706:statistics & numerical data*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002467:Cell Nucleus / Q000378:metabolism*; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D007484:Iowa / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D008922:Mississippi / Q000453:epidemiology; D009364:Neoplasm Recurrence, Local / Q000208:ethnology* / Q000378:metabolism*; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000208:ethnology / Q000378:metabolism / Q000556:secondary; D012008:Recurrence; D012097:Repressor Proteins / Q000378:metabolism*; D018570:Risk Assessment; D015534:Trans-Activators; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C089320:MTA1 protein, human; D012097:Repressor Proteins; D015534:Trans-Activators; D006655:Histone Deacetylases
references.citation: Front Biosci. 2006 May 01;11:1388-413
references.pmid: 16368524
references.citation: Neoplasia. 2006 Jan;8(1):59-68
references.pmid: 16533427
references.citation: Oncogene. 2008 Mar 27;27(14):1971-80
references.pmid: 17922032
references.citation: Int J Cancer. 2010 Apr 1;126(7):1538-48
references.pmid: 19810103
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7005-12
references.pmid: 16192588
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: JAMA. 1999 May 5;281(17):1591-7
references.pmid: 10235151
references.citation: Oncol Rep. 2011 Aug;26(2):343-8
references.pmid: 21617866
references.citation: Cancer Sci. 2006 May;97(5):374-9
references.pmid: 16630134
references.citation: Br J Cancer. 1999 Apr;79(11-12):1723-6
references.pmid: 10206283
references.citation: J Urol. 2003 Feb;169(2):517-23
references.pmid: 12544300
references.citation: World J Urol. 2013 Apr;31(2):275-80
references.pmid: 22441310
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4300-5
references.pmid: 19636023
references.citation: J Biol Chem. 1994 Sep 16;269(37):22958-63
references.pmid: 8083195
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):665-71
references.pmid: 21307303
references.citation: Cancer Causes Control. 2013 Feb;24(2):297-303
references.pmid: 23224323
references.citation: Med Sci Monit. 2011 Feb;17(2):CR104-9
references.pmid: 21278686
references.citation: Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):222-7
references.pmid: 14734473
references.citation: Cancer. 2005 Jul 15;104(2):290-8
references.pmid: 15948174
references.citation: Prostate. 2011 Feb 15;71(3):268-80
references.pmid: 20717904
references.citation: J Clin Endocrinol Metab. 2007 Jul;92(7):2519-25
references.pmid: 17456570
references.citation: Cancer Res. 2004 Feb 1;64(3):825-9
references.pmid: 14871807
references.citation: Prostate Cancer. 2011;2011:239460
references.pmid: 22135747
references.citation: Lung Cancer. 2002 Feb;35(2):149-54
references.pmid: 11804687
references.citation: PLoS One. 2013;8(3):e57542
references.pmid: 23469203
references.citation: BJU Int. 2012 Oct;110(8):1122-8
references.pmid: 22373045
references.citation: Open Biochem J. 2008;2:100-7
references.pmid: 18949081
references.citation: Int Urol Nephrol. 2012 Aug;44(4):1031-8
references.pmid: 22315156
references.citation: Int J Oncol. 2000 Jun;16(6):1211-4
references.pmid: 10811997
references.citation: Mol Cell. 1998 Dec;2(6):851-61
references.pmid: 9885572
references.citation: Curr Opin Urol. 2010 May;20(3):185-8
references.pmid: 20224413
references.citation: Nature. 2002 Aug 8;418(6898):654-7
references.pmid: 12167865
references.citation: J Urol. 2013 May;189(5):1707-12
references.pmid: 23159265